These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16628682)

  • 1. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis.
    Dan YY; Wai CT; Yeoh KG; Lim SG
    Liver Transpl; 2006 May; 12(5):736-46. PubMed ID: 16628682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
    Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
    Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.
    Katz LH; Tur-Kaspa R; Guy DG; Paul M
    Cochrane Database Syst Rev; 2010 Jul; (7):CD006005. PubMed ID: 20614442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.